KCNQ5 and early-onset autosomal dominant Alzheimer disease: Our MR results suggest that inhibition of RERE and KCNQ5 could be used to treat schizophrenia and GPNMB to treat Parkinson’s disease whereas promotion of SUOX could be used to treat Anorexia and ACE to treat Alzheimer’s disease.